Download PDF
Aktuelle Neurologie 2005; 32(8): 481-495
DOI: 10.1055/s-2005-866916
Fort- und Weiterbildung
© Georg Thieme Verlag KG Stuttgart · New York

Drogen und Nervensystem (Teil 1): Mechanismen der Abhängigkeit

Drugs and Nervous System (Part 1): Mechanisms of DependencyS.  Rüegg1
  • 1Abteilung für Klinische Neurophysiologie, Neurologische Klinik, Universitätsspital Basel, Schweiz
Further Information

Publication History

Publication Date:
30 September 2005 (online)

Also available at
    Permissions and Reprints

Weiterbildungsziele In diesem Beitrag sollen folgende Weiterbildungsziele vermittelt werden: Kenntnis der Drogenklassen und der einzelnen wichtigsten Vertreter Kenntnis der grundlegenden Wirkungsmechanismen von Drogen Kenntnis der wichtigsten Interaktionsstellen der Drogen (Rezeptoren/Transporter) Entstehung von Abhängigkeit

Literatur

  • 1 Botré F. Drugs of abuse and abuse of drugs in sportsmen: the role of in vitro models to study effects and mechanisms.  Toxicol In Vitro. 2003;  17 509-513
    CrossrefPubMedGoogle Scholar
  • 2 Chiara G Di, Acquas E, Tanda G, Cadoni C. Drugs of abuse: biochemical surrogates of specific aspects of natural reward?.  Biochem Soc Symp. 1993;  59 65-81
    PubMedGoogle Scholar
  • 3 Neiman J, Haapaniemi H M, Hilborn M. Neurological complications of drug abuse: pathophysiological mechanisms.  Eur J Neurol. 2000;  7 595-606
    CrossrefPubMedGoogle Scholar
  • 4 Kreek M J. Drug Addictions. Molecular and cellular endpoints.  Ann N Y Acad Sci. 2001;  937 27-46
    PubMedGoogle Scholar
  • 5 González M I, Robinson M B. Neurotransmitter transporters: why dance with so many partners?.  Curr Opin Pharmacol. 2004;  4 30-35
    PubMedGoogle Scholar
  • 6 Kobayashi H, Suzuki T, Kamata R. et al . Recent progress in the neurotoxicology of natural drugs associated with dependence or addiction, their endogenous agonists and receptors.  J Toxicol Sci. 1999;  24 1-16
    PubMedGoogle Scholar
  • 7 Pert C B, Snyder S H. Opiate receptor: demonstration in nervous tissue.  Science. 1973;  179 1011-1014
    CrossrefPubMedGoogle Scholar
  • 8 Devane W A, Dysarz 3rd  F A, Johnson M R. et al . Determination and characterization of a cannabinoid receptor in rat brain.  Mol Pharmacol. 1988;  34 605-613
    PubMedGoogle Scholar
  • 9 Matsuda L A, Lolait S J, Brownstein M J. et al . Structure of a cannabinoid receptor and functional expression of cloned DNA (cDNA).  Nature. 1990;  346 561-564
    CrossrefPubMedGoogle Scholar
  • 10 Hughes J, Smith T W, Kosterlitz H W. et al . Identification of two related pentapeptides from the brain with potent opiate agonist activity.  Nature. 1975;  258 577-580
    PubMedGoogle Scholar
  • 11 Devane W A, Hanus L, Breuer A. et al . Isolation and structure of a brain constituent that binds to the cannabinoid receptor.  Science. 1992;  258 1946-1949
    CrossrefPubMedGoogle Scholar
  • 12 Nutt D J. Addiction: brain mechanisms and their treatment implications.  Lancet. 1996;  347 31-36
    CrossrefPubMedGoogle Scholar
  • 13 Nestler E J, Aghajanian G K. Molecular and cellular basis of addiction.  Science. 1997;  278 58-63
    CrossrefPubMedGoogle Scholar
  • 14 Nestler E J. Molecular basis of long-term plasticity underlying addiction.  Nat Rev Neurosci. 2001;  2 119-128
    PubMedGoogle Scholar
  • 15 Wise R A. Neurobiology of addiction.  Curr Opin Neurobiol. 1996;  6 243-251
    CrossrefPubMedGoogle Scholar
  • 16 Wise R A. Drug-activation of brain reward pathways.  Drug Alcohol Depend. 1998;  51 13-22
    PubMedGoogle Scholar
  • 17 Koob G F, Ahmed S H, Boutrel B. et al . Neurobiological mechanisms in the transition from drug use to drug dependence.  Neurosci Biobehav Rev. 2004;  27 739-749
    CrossrefPubMedGoogle Scholar
  • 18 Amara S G, Sonders M S. Neurotransmitter transporters as molecular targets for addictive drugs.  Drug Alcohol Depend. 1998;  51 87-96
    PubMedGoogle Scholar
  • 19 Rothman R B, Baumann M H. Monoamine transporters and psychostimulant drugs.  Eur J Pharmacol. 2003;  479 23-40
    CrossrefPubMedGoogle Scholar
  • 20 Liu Y, Krantz D E, Waites C, Edwards R H. Membrane trafficking of neurotransmitter transporters in the regulation of synaptic transmission.  Trends Cell Biol. 1999;  9 356-363
    CrossrefPubMedGoogle Scholar
  • 21 Laakso A, Mohn A R, Gainetdinov R R, Caron M G. Experimental genetic approaches to addiction.  Neuron. 2002;  36 213-228
    CrossrefPubMedGoogle Scholar
  • 22 Betz C, Mihalic D, Pinto M E, Raffa R B. Could a common biochemical mechanism underlie addictions?.  J Clin Pharm Ther. 2000;  25 11-20
    CrossrefPubMedGoogle Scholar
  • 23 Pulvirenti L, Diana M. Drug dependence as a disorder of neural plasticity: focus on dopamine and glutamate.  Rev Neurosci. 2001;  12 141-158
    PubMedGoogle Scholar
  • 24 Saal D, Dong Y, Bonci A, Malenka R C. Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons.  Neuron. 2003;  37 557-582
    PubMedGoogle Scholar
  • 25 Nakamichi N, Yoneda Y. Transcription factors and drugs in the brain.  Jpn J Pharmacol. 2002;  89 337-348
    CrossrefPubMedGoogle Scholar
  • 26 Lüscher C, Nicoll R A, Malenka R C, Muller D. Synaptic plasticity and dynamic modulation of the postsynaptic membrane.  Nature Neurosci. 2000;  3 545-550
    CrossrefPubMedGoogle Scholar
  • 27 Winder D G, Egli R E, Schramm N L, Matthews R T. Synaptic plasticity in drug reward circuitry.  Curr Mol Med. 2002;  2 667-676
    CrossrefPubMedGoogle Scholar
  • 28 Wolf M E. LTP may trigger addiction.  Mol Intervent. 2003;  3 248-252
    PubMedGoogle Scholar
  • 29 Harlan R E, Garcia M M. Drugs of abuse and immediate-early genes in the forebrain.  Mol Neurobiol. 1998;  16 221-267
    PubMedGoogle Scholar
  • 30 Kauer J A. Learning mechanisms in addiction: Synaptic plasticity in the ventral tegmental area as a result of exposure to drugs of abuse.  Annu Rev Physiol. 2004;  66 447-475
    CrossrefPubMedGoogle Scholar
  • 31 Levitt P. Prenatal effects of drugs of abuse on brain development.  Drug Alcohol Depend. 1998;  51 109-125
    PubMedGoogle Scholar
  • 32 Kosofsky B E, Hyman S E. No time for complacency: the fetal brain on drugs.  J Comp Neurol. 2001;  435 259-262
    PubMedGoogle Scholar
  • 33 Farber N B, Olney J W. Drugs of abuse that cause developing neurons to commit suicide.  Dev Brain Res. 2003;  147 37-45
    CrossrefPubMedGoogle Scholar
  • 34 Greene C M, Goodman M H. Neonatal abstinence syndrome: strategies for care of the drug-exposed infant.  Neonatal Netw. 2003;  22 15-25
    PubMedGoogle Scholar
  • 35 Koob G F, Moal M Le. Drug addiction, dysregulation of reward, and allostasis.  Neuropsychopharmacology. 2001;  24 97-129
    CrossrefPubMedGoogle Scholar
  • 36 Jacobs E H, Smit A B, Vries T J de, Schoffelmeer A NM. Neuroadaptive effects of active versus passive drug administration in addiction research.  Trends Pharmacol Sci. 2003;  24 566-573
    CrossrefPubMedGoogle Scholar
  • 37 Kosten T R, O'Connor P G. Management of drug and alcohol withdrawal.  New Engl J Med. 2003;  348 1786-1795
    CrossrefPubMedGoogle Scholar
  • 38 Lu L, Hope B T, Dempsey J. et al . Central amygdala ERK signalling pathway is critical to incubation of cocaine craving.  Nature Neurosci. 2005;  8 212-219
    CrossrefPubMedGoogle Scholar
  • 39 Smith R F. Animal models of periadolescent substance abuse.  Neurotoxicol Teratol. 2003;  25 291-301
    CrossrefPubMedGoogle Scholar
  • 40 Iacono W G, Malone S M, McGue M. Substance use disorders, externalizing psychopathology, and P300 event-related potential amplitude.  Int J Psychopathol. 2003;  48 147-178
    PubMedGoogle Scholar
  • 41 Little H J. The contribution of electrophysiology to knowledge of the acute and chronic effects of ethanol.  Pharmacol Ther. 1999;  84 333-353
    CrossrefPubMedGoogle Scholar
  • 42 Mendelssohn A de, Kasper S, Tauscher J. Neuroimaging bei Substanzabhängigkeit.  Nervenarzt. 2004;  75 651-662
    PubMedGoogle Scholar
  • 43 Wilson S J, Sayette M A, Fiez J A. Prefrontal responses to drug cues: a neurocognitive analysis.  Nature Neurosci. 2004;  7 211-214
    CrossrefPubMedGoogle Scholar
  • 44 Volkow N D, Fowler J S, Wang G J. The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies.  Neuropharmacology. 2004;  47 3-13
    Google Scholar
  • 45 Sullivan E V, Pfefferbaum A. Diffusion tensor imaging in normal aging and neuropsychiatric disorders.  Eur J Radiol. 2003;  45 244-255
    CrossrefPubMedGoogle Scholar
  • 46 Rosenbloom M, Sullivan E, Pfefferbaum A. Using magnetic resonance imaging and diffusion tensor imaging to assess brain damage in alcoholics.  Alcohol Res Health. 2003;  27 146-152
    PubMedGoogle Scholar
  • 47 Melichar J K, Hume S P, Williams T M. et al . Using [11C]Diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies.  J Pharmacol Exp Ther. 2005;  312 309-315
    PubMedGoogle Scholar
  • 48 Kreek M J. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine.  Ann N Y Acad Sci. 2000;  909 186-216
    PubMedGoogle Scholar
  • 49 Haasen C, Krausz M. Myths versus evidence with respect to cocaine and crack: Learning from the US experience.  Eur Addict Res. 2001;  7 159-160
    CrossrefPubMedGoogle Scholar
  • 50 Emilien G, Maloteaux J M, Geurts M. et al . Dopamine receptors - physiological understanding to therapeutic intervention potential.  Pharmacol Ther. 1999;  84 133-156
    CrossrefPubMedGoogle Scholar
  • 51 Self D W. Regulation of drug-taking and -seeking behaviours by neuroadaptations in the mesolimbic dopamine system.  Neuropsychopharmacology. 2004;  47 (Suppl 1) S242-S255
    PubMedGoogle Scholar
  • 52 Salter M W. D1 and NMDA receptors hook up: expanding on an emerging theme.  Trends Neurosci. 2003;  26 235-237
    CrossrefPubMedGoogle Scholar
  • 53 Richtand N M, Goldsmith R J, Nolan J E, Berger S P. The D3 dopamine receptor and substance dependence.  J Addict Dis. 2001;  20 19-32
    CrossrefPubMedGoogle Scholar
  • 54 Noda Y, Nabeshima T. Opiate physical dependence and N-methyl-D-aspartate receptors.  Eur J Pharmacol. 2004;  500 121-128
    CrossrefPubMedGoogle Scholar
  • 55 Siggins G R, Martin G, Roberto M. et al . Glutamatergic transmission in opiate and alcohol dependence.  Ann N Y Acad Sci. 2003;  1003 196-211
    CrossrefPubMedGoogle Scholar
  • 56 Loftis J M, Janowsky A. Cocaine treatment- and withdrawal-induced alterations in the expression and serine phosphorylation of the NR1 NMDA receptor subunit.  Psychopharmacology. 2002;  164 349-359
    CrossrefPubMedGoogle Scholar
  • 57 Loftis J M, Janowsky A. The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications.  Pharmacol Ther. 2003;  97 55-85
    CrossrefPubMedGoogle Scholar
  • 58 Kalivas P W. Glutamate systems in cocaine addiction.  Curr Opin Pharmacol. 2004;  4 23-29
    PubMedGoogle Scholar
  • 59 Carlezon Jr W A, Nestler E J. Elevated levels of GluR1 in the midbrain: a trigger for sensitization to drugs of abuse?.  Trends Neurosci. 2002;  25 610-615
    CrossrefPubMedGoogle Scholar
  • 60 Kenny P J, Markou A. The ups and downs of addiction: role of metabotropic glutamate receptors.  Trends Pharmacol Sci. 2004;  25 265-272
    CrossrefPubMedGoogle Scholar
  • 61 Kumar S, Fleming R L, Morrow A L. Ethanol regulation of gamma-aminobutyric acid A receptors: genomic and nongenomic mechanisms.  Pharmacol Ther. 2004;  101 211-226
    CrossrefPubMedGoogle Scholar
  • 62 Cousins M S, Roberts D C, Witt H de. GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings.  Drug Alcohol Depend. 2002;  65 209-220
    PubMedGoogle Scholar
  • 63 Dani J A. Overview of nicotinic receptors and their roles in the central nervous system.  Biol Psychiatry. 2001;  49 166-174
    CrossrefPubMedGoogle Scholar
  • 64 Homberg J R, Raaso H S, Schoffelmeer A NM, Vries T J de. Individual differences in sensitivity to factors provoking reinstatement of cocaine-seeking behavior.  Behav Brain Res. 2004;  152 157-161
    PubMedGoogle Scholar
  • 65 Zhang L C, Buccafusco J J. Prevention of morphine-induced muscarinic (M2) receptor adaptation suppresses the expression of withdrawal symptoms.  Brain Res. 1998;  803 114-121
    CrossrefPubMedGoogle Scholar
  • 66 Fink-Jensen A, Fedorova I, Wörtwein G. et al . Role for M5 muscarinic acetylcholine receptors in cocaine addicition.  J Neurosci Res. 2003;  74 91-96
    CrossrefPubMedGoogle Scholar
  • 67 Roth B L, Willins D L, Kroeze W K. G protein-coupled receptor (GPCR) trafficking in the central nervous system: relevance for drugs of abuse.  Drug Alcohol Depend. 1998;  51 73-85
    PubMedGoogle Scholar
  • 68 Grant K A. The role of 5-HT3 receptors in drug dependence.  Drug Alcohol Depend. 1995;  38 155-171
    PubMedGoogle Scholar
  • 69 Daly J W, Fredholm B B. Caffeine - an atypical drug of dependence.  Drug Alcohol Depend. 1998;  51 199-206
    PubMedGoogle Scholar
  • 70 Hack S P, Christie M J. Adaptations in adenosine signaling in drug dependence: therapeutic implications.  Crit Rev Neurobiol. 2003;  15 235-274
    PubMedGoogle Scholar
  • 71 Moreau J L, Huber G. Central adenosine A2A receptors: an overview.  Brain Res Rev. 1999;  31 65-82
    CrossrefPubMedGoogle Scholar
  • 72 Baraldi P G, Cacciari B, Romagnoli R. et al . A3 adenosine receptor ligands: history and perspectives.  Med Res Rev. 2000;  20 103-128
    CrossrefPubMedGoogle Scholar
  • 73 Reis D J, Regunathan S. Is agmatine a novel neurotransmitter in brain?.  Trends Pharmacol Sci. 2000;  21 187-193
    CrossrefPubMedGoogle Scholar
  • 74 García-Sevilla J A, Escribá P V, Guimón J. Imidazoline receptors and human brain disorders.  Ann N Y Acad Sci. 1999;  881 392-409
    PubMedGoogle Scholar
  • 75 Howlett A C, Breivogel C S, Childers S R. et al . Cannabinoid physiology and pharmacology: 30 years of progress.  Neuropharmacology. 2004;  47 345-358
    CrossrefPubMedGoogle Scholar
  • 76 Iversen L. Cannabis and the brain.  Brain. 2003;  126 1252-1270
    Google Scholar
  • 77 Ralevic V. Cannabinoid modulation of peripheral autonomic and sensory neurotransmission.  Eur J Pharmacol. 2003;  472 1-21
    CrossrefPubMedGoogle Scholar
  • 78 Nestler E J. Molecular mechanisms of drug addiction.  Neuropharmacology. 2004;  47 (Suppl 1) S24-S32
    CrossrefPubMedGoogle Scholar
  • 79 Isola R, Zhang H, Duchemin A M. et al . Met-enkephalin and preproenkephalin mRNA changes in the striatum of the nicotine abstinence mouse.  Neurosci Lett. 2002;  325 67-71
    CrossrefPubMedGoogle Scholar
  • 80 Plotkin S R, Banks W A, Cohn C S, Kastin A J. Withdrawal from alcohol in withdrawal seizure-prone and -resistant mice: evidence for enkephalin resistance.  Pharmacol Biochem Behav. 2001;  68 379-387
    CrossrefPubMedGoogle Scholar
  • 81 Nylander I, Vlaskovska M, Terenius L. The effects of morphine treatment and morphine withdrawal on the dynorphin and enkephalin systems in Sprague-Dawley rats.  Psychopharmacology. 1995;  118 391-400
    PubMedGoogle Scholar
  • 82 Akil H, Owens C, Gutstein H. et al . Endogenous opioids: overview and current issues.  Drug Alcohol Depend. 1998;  51 127-140
    PubMedGoogle Scholar
  • 83 Kreek M J. Opioid receptors: some perspectives from early studies of their role in normal physiology, stress responsivity, and in specific addictive diseases.  Neurochem Res. 1996;  21 1469-1488
    PubMedGoogle Scholar
  • 84 Ciccocioppo R, Angeletti S, Panocka I, Massi M. Nociceptin/orphanin FQ and drugs of abuse.  Peptides. 2000;  21 1071-1080
    CrossrefPubMedGoogle Scholar
  • 85 Meunier J C. Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor.  Eur J Pharmacol. 1997;  340 1-15
    CrossrefPubMedGoogle Scholar
  • 86 Hanson G R, Singh N, Merchant K. et al . Responses of limbic and extrapyramidal neurotensin systems to stimulants of abuse. Involvement of dopaminergic mechanisms.  Ann N Y Acad Sci. 1992;  668 165-172
    PubMedGoogle Scholar
  • 87 Richelson E, Boules M, Frederickson P. Neurotensin agonists: possible drugs for treatment of psychostimulant abuse.  Life Sci. 2003;  73 679-690
    CrossrefPubMedGoogle Scholar
  • 88 Sarnyai Z, Kovacs G L. Role of oxytocin in the neuroadaptation to drugs of abuse.  Psychoneuroendocrinology. 1994;  19 85-117
    CrossrefPubMedGoogle Scholar
  • 89 Kovács G L, Darnyai Z, Szabó G. Oxytocin and addiction: a review.  Psychoneuroendocrinology. 1998;  23 945-962
    CrossrefPubMedGoogle Scholar
  • 90 Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation.  Physiol Rev. 2001;  81 629-683
    CrossrefPubMedGoogle Scholar
  • 91 Zingg H H, Laporte S A. The oxytocin receptor.  Trends Endocrinol Metab. 2003;  14 222-227
    PubMedGoogle Scholar
  • 92 Zachariou V, Thome J, Parikh K, Picciotto M R. Upregulation of galanin binding sites and GalR1 mRNA levels in the mouse locus coeruleus following chronic morphine treatments and precipitated morphine withdrawal.  Neuropsychopharmacology. 2000;  23 127-137
    CrossrefPubMedGoogle Scholar
  • 93 Zachariou V, Brunzell D H, Hawes J. et al . The neuropeptide galanin modulates behavioural and neurochemical signs of opiate withdrawal.  Proc Natl Acad Sci U.S.A.. 2003;  100 9028-9033
    CrossrefPubMedGoogle Scholar
  • 94 Takahashi L K. Role of CRF(1) and CRF(2) receptors in fear and anxiety.  Neurosci Biobehav Rev. 2001;  25 627-636
    CrossrefPubMedGoogle Scholar
  • 95 Roumy M, Garnier M, Zajac J M. Neuropeptide FF receptors 1 and 2 exert an anti-opioid activity in acutely dissociated rat dorsal raphe and periventricular hypothalamic neurones.  Neurosci Lett. 2003;  348 159-162
    CrossrefPubMedGoogle Scholar
  • 96 Gouarderes C, Puget A, Zajac J M. et al . Neuropeptide Y (NPY) in stress and alcohol dependence.  Rev Neurosci. 2002;  13 85-94
    PubMedGoogle Scholar
  • 97 Nystedt J M, Lemberg K, Lintunen M. et al . Pain- and morphine-associated transcriptional regulation of neuropeptide FF and the G-protein-coupled NPFF2 receptor gene.  Neurobiol Dis. 2004;  16 254-262
    CrossrefPubMedGoogle Scholar
  • 98 Blomqvist A G, Herzog H. Y-receptors subtypes - how many more?.  Trends Neurosci. 1997;  20 294-298
    CrossrefPubMedGoogle Scholar
  • 99 Chronwall B M, Zukowska Z. Neuropeptide Y, ubiquitous and elusive.  Peptides. 2004;  25 359-363
    CrossrefPubMedGoogle Scholar
  • 100 Heilig M, Thorsell A. Neuropeptide Y (NPY) in stress and alcohol dependence.  Rev Neurosci. 2002;  13 85-94
    PubMedGoogle Scholar

Dr. med. Stephan Rüegg

Abt. für Klinische Neurophysiologie · Neurologische Klinik · Universitätsspital

Petersgraben 4

4031 Basel · Schweiz

Email: srueegg@uhbs.ch